| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 16, 2021 | NBIX Neurocrine Biosciences Inc | Benevich Eric62 | Chief Commercial Officer | Sell | 5,628 | $89.62 | $504,394.87 | -26.5% | -2.7% | +17.7% | |
| Aug 16, 2021 | IRWD Ironwood Pharmaceuticals Inc | Rickard Jason65 | SVP, Chief Operating Officer | Sell | 680 | $13.48 | $9,166.40 | -0.2% | -8.8% | -10.2% | |
| Aug 16, 2021 | LNTH Lantheus Holdings, Inc. | Sabens Andrea47 | Chief Accounting Officer | Sell | 1,242 | $25.46 | $31,621.32 | -1.8% | +19.3% | +233.8% | |
| Aug 16, 2021 | ELAN Elanco Animal Health Inc | Hoover R David50 | See Remarks | Buy | 10,000 | $31.31 | $313,082.00 | +6.2% | +2.0% | -39.5% | |
| Aug 13, 2021 | PFE Pfizer Inc | Damico Jennifer B.58 | SVP &Controller | Sell | 1,661 | $48.30 | $80,226.29 | -7.3% | +4.4% | +6.7% | |
| Aug 13, 2021 | TXMD Therapeuticsmd, Inc. | Thompson Tommy G51 | Director | Buy | 11,000 | $0.87 | $9,570.00 | +1.6% | -23.4% | -78.6% | |
| Aug 12, 2021 | BMY Bristol Myers Squibb Co | Elkins David V | EVP, Chief Financial Officer | Sell | 99,691 | $66.95 | $6,674,497.00 | -40.0% | -10.6% | +16.4% | |
| Aug 12, 2021 | AMRN Amarin Corp Plc\uk | Kalb Michael Wayne | SVP And CFO | Sell | 120,000 | $5.25 | $630,240.00 | -36.9% | -25.5% | -70.7% | |
| Aug 12, 2021 | ANIK Anika Therapeutics, Inc. | Levitz Michael L | EVP, CFO, Treasurer | Buy | 3,627 | $40.21 | $145,826.39 | +34.3% | -4.6% | -45.0% | |
| Aug 12, 2021 | TXMD Therapeuticsmd, Inc. | Darecca James | Chief Financial Officer | Sell | 93,337 | $0.87 | $81,203.19 | -43.0% | -19.6% | -79.3% | |
| Aug 11, 2021 | DVAX Dynavax Technologies Corp | Janssen Robert71 | Senior Vice President | Sell | 49,583 | $12.06 | $597,970.98 | -87.8% | +31.7% | +37.6% | |
| Aug 11, 2021 | DVAX Dynavax Technologies Corp | Novack David F73 | President &COO | Sell | 10,000 | $12.00 | $120,000.00 | -8.5% | +31.7% | +37.6% | |
| Aug 11, 2021 | ELAN Elanco Animal Health Inc | Simmons Jeffrey N52 | President, CEO &Director | Buy | 16,850 | $29.70 | $500,445.00 | +3.1% | +13.4% | -33.0% | |
| Aug 11, 2021 | ELAN Elanco Animal Health Inc | Harrington Michael J | Director | Buy | 3,000 | $28.99 | $86,955.00 | +13.2% | +13.4% | -33.0% | |
| Aug 10, 2021 | TEVA Teva Pharmaceutical Industries Ltd | Fridriksdottir Hafrun47 | Executive VP, Global R&D | Sell | 50,860 | $9.95 | $506,021.40 | -55.1% | -7.7% | +10.9% | |
| Aug 10, 2021 | LNTH Lantheus Holdings, Inc. | Heino Mary Anne50 | President &CEO | Sell | 15,580 | $25.83 | $402,369.08 | -2.2% | +14.6% | +222.6% | |
| Aug 9, 2021 | DVAX Dynavax Technologies Corp | Hack Andrew A. F.62 | Director | Sell | 2,250,000 | $10.80 | $24,300,000.00 | -20.9% | +39.3% | +47.0% | |
| Aug 9, 2021 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 104,711 | $267.50 | $28,010,134.51 | - | -2.2% | +15.0% | |
| Aug 6, 2021 | DVAX Dynavax Technologies Corp | Janssen Robert71 | Senior Vice President | Sell | 80,000 | $10.75 | $860,000.00 | -92.1% | +93.3% | +55.0% | |
| Aug 6, 2021 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 7,597 | $264.05 | $2,005,965.06 | - | +3.2% | +16.0% | |
| Aug 6, 2021 | UTHR United Therapeutics Corp | Causey Christopher59 | Director | Sell | 2,610 | $210.00 | $548,100.00 | -77.7% | -5.6% | +3.9% | |
| Aug 6, 2021 | HIMS Hims & Hers Health, Inc. | Abraham Jack | 10% Owner | Sell | 98,669 | $0.00 | - | -0.4% | +2.3% | -19.6% | |
| Aug 6, 2021 | ETON Eton Pharmaceuticals, Inc. | Opaleye Management Inc.60 | 10% Owner | Sell | 604,500 | $5.83 | $3,523,187.20 | -5.6% | +9.4% | -49.9% | |
| Aug 5, 2021 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 132,692 | $264.26 | $35,065,320.39 | - | +1.1% | +15.7% | |
| Aug 5, 2021 | BHC Bausch Health Companies Inc. | Von Eschenbach Andrew C. | Director | Buy | 1,400 | $25.94 | $36,316.00 | +3.8% | +5.1% | -78.4% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.